Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets

Kristoffer Hellstrand • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Kristoffer Hellstrand, MD, PhD, discusses his group’s aims and ongoing work at Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden, which includes both basic research and the clinical development of agents. Prof. Hellstrand also discusses a recent publication from his group on how HLA-B-21 dimorphism impacts NK-cell function and the clinical outcome of immunotherapy in acute myeloid leukemia (AML).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Kristoffer Hellstrand

Histamine dihydrochloride to prevent relapse in AML: development and ongoing research
3:43
Histamine dihydrochloride to prevent relapse in AML: development and ongoing research
Kristoffer Hellstrand • 1 Mar 2019
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
1:22
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Kristoffer Hellstrand • 19 Feb 2017
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
1:17
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand • 19 Feb 2017

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals